Daiichi Sankyo begins ELDERCARE-AF Study

Daiichi Sankyo Company, Ltd have announced that it has initiated the ELDERCARE-AF (edoxaban low-dose for elder care AF patients) study aimed at additional dosage and formulation for patients with non-valvular atrial fibrillation for the anticoagulant edoxaban developed by Daiichi Sankyo (Edoxaban Tosilate Hydrate).

This study is a phase 3 clinical trial in Japan to verify the safety and efficacy (prevention of stroke and systemic embolism) of 15 mg once-daily oral administration of edoxaban to non-valvular atrial fibrillation patients who are not eligible for current available oral anticoagulation therapy with an approved dose regimen of VKA (vit K antagonist) or DOACs (direct oral anticoagulants) and are aged 80 years and older.

Press release from http://www.daiichisankyo.com



Related Topics and Keywords

, , ,

Subscribe to our FREE newsletter and WEBINAR UPDATES

We will not sell or give your information to a third party. See our Privacy Policy